Kawamoto Hironori, Takasaki Jin, Ishii Satoru, Suzuki Manabu, Morino Eriko, Naka Go, Iikura Motoyasu, Izumi Shinyu, Takeda Yuichiro, Sugiyama Haruhito
Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Division of Respiratory Diseases, Department of Internal Medicine, National Center for Global Health and Medicine, Tokyo, Japan.
Respir Med Case Rep. 2017 Apr 15;21:147-150. doi: 10.1016/j.rmcr.2017.04.013. eCollection 2017.
This case report describes the re-administration of abatacept to successfully reduce the articularsymptoms of a patient with rheumatoid arthritisduring the intensive phase of anti-tuberculous therapy. A 75-year-old man developed active pulmonary tuberculosis during the administration of abatacept for rheumatoid arthritis. The patient experienced a paradoxical reaction and exacerbation of rheumatoid arthritis that caused us to discontinue the abatacept. Later re-administration of abatacept along with anti-tuberculosis treatment led to well-controlled rheumatoid arthritis without exacerbation of the tuberculosis. This case shows that re-administration of abatacept may be much safer than TNF inhibitor to treat patients who are infected with mycobacteria during thetreatment of immunological diseases such asrheumatoid arthritiswith biological agents.
本病例报告描述了在抗结核治疗强化期重新使用阿巴西普成功减轻类风湿关节炎患者关节症状的情况。一名75岁男性在使用阿巴西普治疗类风湿关节炎期间发生了活动性肺结核。患者出现了矛盾反应和类风湿关节炎加重,导致我们停用了阿巴西普。后来重新使用阿巴西普并联合抗结核治疗,使类风湿关节炎得到良好控制,且未导致结核病加重。该病例表明,对于在使用生物制剂治疗类风湿关节炎等免疫性疾病期间感染分枝杆菌的患者,重新使用阿巴西普可能比使用肿瘤坏死因子抑制剂更安全。